Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

Mark Attanasio on the Length of the Credit Cycle
21:44 - Mark Attanasio, managing partner of Crescent Capital Group, talks to Bloomberg's Erik Schatzker about the state of the credit cycle. (Source: Bloomberg)
  • Where to Invest Amid Risk
  • Should Investors Be Wary of Emerging Markets?
  • The Road Ahead for Municipalities